{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T07:56:46Z","timestamp":1764403006541,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Egypt Heart J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Direct-acting antiviral agents (DAAs) cure patients with hepatitis C virus (HCV) infection. Concerns have arisen the occurrence of significant bradyarrhythmias during treatment with DAAs. The aim of this study was to assess the impact of a DAA combination for the treatment of HCV infection on heart rate, rhythm, and heart rate variability (HRV) using 24-h ECG monitoring.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>A prospective randomized study of 50 treatment-na\u00efve patients with HCV infection treated with a combination of sofosbuvir 400 mg daily and daclatasvir 60 mg daily for 12 weeks. Surface ECG and 24-h ECG monitoring were performed at baseline and after completion of therapy to assess PR interval, corrected QT interval (QTc), minimum heart rate (HR), maximum HR, average HR, HRV time-domain and frequency-domain measures, significant pauses, tachycardias, bradycardias, premature atrial contractions (PACs), and premature ventricular contraction (PVCs).<\/jats:p>\n<jats:p>No differences were detected in all examined parameters between baseline and after completion of treatment. PR interval was 154 \u00b1 25.95 vs 151.4 \u00b1 23.82 ms, respectively (<jats:italic>p<\/jats:italic> = 0.124). QTc interval was 397.34 \u00b1 29.38 vs 395.04 \u00b1 30.23 ms, respectively (<jats:italic>p<\/jats:italic> = 0.403). No differences were detected for minimum HR, maximum HR, average HR, HRV time-domain and frequency-domain measures, the occurrence of significant pauses, sinus tachycardia episodes, sinus bradycardia episodes, PACs, and PVCs. No episodes of bradyarrhythmias, syncope, and atrial fibrillation, supraventricular, or ventricular tachycardias were reported or detected.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>In non-cardiac patients receiving no cardioactive medications, the combination of sofosbuvir and daclatasvir for the treatment of HCV infection has no effect on HR, rhythm, conductivity, or HRV. No symptomatic bradycardias, tachycardias, or syncope were reported or detected using 24-h ECG monitoring.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s43044-020-00070-4","type":"journal-article","created":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T07:53:05Z","timestamp":1593589985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Assessing the impact of a combination of sofosbuvir and daclatasvir treatment for hepatitis C virus infection on heart rate, rhythm and heart rate variability using 24-hour ECG monitoring"],"prefix":"10.1186","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4206-1760","authenticated-orcid":false,"given":"Ahmed Mohamed","family":"El Missiri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona Mostafa","family":"Rayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Medhat","family":"Awad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Ibrahim","family":"El Desoky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,1]]},"reference":[{"key":"70_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/hep.27259","volume":"61","author":"J Messina","year":"2015","unstructured":"Messina J, Humphreys I, Flaxman A et al (2015) Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61:77\u201387","journal-title":"Hepatology"},{"key":"70_CR2","doi-asserted-by":"publisher","first-page":"17006","DOI":"10.1038\/nrdp.2017.6","volume":"3","author":"MP Manns","year":"2017","unstructured":"Manns MP, Buti M, Gane E et al (2017) Hepatitis C virus infection. Nat Rev Dis Primers 3:17006","journal-title":"Nat Rev Dis Primers"},{"key":"70_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1053\/j.gastro.2015.09.007","volume":"150","author":"S Petta","year":"2016","unstructured":"Petta S, Maida M, Macaluso F et al (2016) Hepatitis C virus infection is associated with increased cardiovascular mortality: a meta-analysis of observational studies. Gastroenterology 150:145\u2013155","journal-title":"Gastroenterology"},{"issue":"8","key":"70_CR4","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nrd4050","volume":"12","author":"MP Manns","year":"2013","unstructured":"Manns MP, von Hahn T (2013) Novel therapies for hepatitis C\u2014one pill fits all? Nat Rev Drug Discov 12(8):595\u2013610","journal-title":"Nat Rev Drug Discov"},{"key":"70_CR5","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMp1311439","volume":"369","author":"R Sherman","year":"2013","unstructured":"Sherman R, Li J, Shapley S et al (2013) Expediting drug development\u2014the FDA\u2019s new \u201cbreakthrough therapy\u201d designation. N Engl J Med 369:1877\u20131880","journal-title":"N Engl J Med"},{"issue":"19","key":"70_CR6","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1056\/NEJMc1505967","volume":"373","author":"H Fontaine","year":"2015","unstructured":"Fontaine H, Lazarus A, Pol S et al (2015) Bradyarrhythmias associated with sofosbuvir treatment. N Engl J Med 373(19):1886\u20131888","journal-title":"N Engl J Med"},{"issue":"4","key":"70_CR7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s12664-016-0684-6","volume":"35","author":"A Ghembaza Mel","year":"2016","unstructured":"Ghembaza Mel A, Lounici A et al (2016) Bradyarrhythmia induced by amiodarone-sofosbuvir co-administration. Indian J Gastroenterol 35(4):319\u2013320","journal-title":"Indian J Gastroenterol"},{"issue":"19","key":"70_CR8","first-page":"1888","volume":"373","author":"DM Brainard","year":"2015","unstructured":"Brainard DM, McHutchison JG (2015) Bradyarrhythmias associated with sofosbuvir treatment. N Engl J Med 373(19):1888","journal-title":"N Engl J Med"},{"issue":"1","key":"70_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","volume":"66","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver (2017) EASL recommendations on treatment of hepatitis C 2016. J Hepatol 66(1):153\u2013194","journal-title":"J Hepatol"},{"key":"70_CR10","doi-asserted-by":"crossref","unstructured":"Goldberger A, Goldberger Z, Shvilkin A. (2013) Goldberger\u2019s clinical electrocardiography. ECG basics: waves, intervals, and segments. 8th edition;2: 8-14.","DOI":"10.1016\/B978-0-323-08786-5.00001-4"},{"issue":"4","key":"70_CR11","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/j.1464-5491.1995.tb00481.x","volume":"12","author":"M Veglio","year":"1995","unstructured":"Veglio M, Chinaglia A, Borra M et al (1995) Does abnormal QT interval prolongation reflect autonomic dysfunction in diabetic patients? QTc interval measure versus standardized tests in diabetic autonomic neuropathy. Diabet Med 12(4):302\u2013306","journal-title":"Diabet Med"},{"issue":"1","key":"70_CR12","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/j.1542-474X.2005.10101.x","volume":"10","author":"RE Kleiger","year":"2005","unstructured":"Kleiger RE, Stein PK, Bigger JT Jr (2005) Heart rate variability: measurement and clinical utility. Ann Noninvasive Electrocardiol 10(1):88\u2013101","journal-title":"Ann Noninvasive Electrocardiol"},{"issue":"5","key":"70_CR13","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1161\/01.CIR.93.5.1043","volume":"93","author":"TF Report","year":"1996","unstructured":"Report TF (1996) Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Circulation 93(5):1043\u20131065","journal-title":"Circulation"},{"key":"70_CR14","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3389\/fpubh.2017.00258","volume":"5","author":"F Shaffer","year":"2017","unstructured":"Shaffer F, Ginsberg JP (2017 Sep 28) An overview of heart rate variability metrics and norms. Front Public Health. 5:258","journal-title":"Front Public Health."},{"key":"70_CR15","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1002\/hep.22127","volume":"47","author":"S Kamal","year":"2008","unstructured":"Kamal S, Nasser I (2008) Hepatitis C genotype 4: what we know and what we don\u2019t yet know. Hepatology 47:1371\u20131383","journal-title":"Hepatology"},{"key":"70_CR16","doi-asserted-by":"crossref","unstructured":"Biomy R, Abdelshafy M, Abdelmonem A et al (2017) Effect of chronic hepatitis C virus treatment by combination therapy on cardiovascular system. Clin Med Insights Cardiol:11","DOI":"10.1177\/1179546817713204"},{"key":"70_CR17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/hep.27488","volume":"62","author":"T Ahmad","year":"2015","unstructured":"Ahmad T, Yin P, Saffitz J et al (2015) Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. Hepatology 62:409\u2013416","journal-title":"Hepatology"},{"issue":"1","key":"70_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s40264-017-0586-2","volume":"41","author":"D Caldeira","year":"2018","unstructured":"Caldeira D, Rodrigues FB, Duarte MM et al (2018) Cardiac harms of sofosbuvir: systematic review and meta-analysis. Drug Saf 41(1):77\u201386","journal-title":"Drug Saf"},{"issue":"7","key":"70_CR19","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/jcph.872","volume":"57","author":"E Durante-Mangoni","year":"2017","unstructured":"Durante-Mangoni E, Parrella A, Vitrone M et al (2017) Electrophysiological adverse effects of direct acting antivirals in patients with chronic hepatitis C. J Clin Pharmacol 57(7):924\u2013930","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"70_CR20","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.dld.2018.09.012","volume":"51","author":"C Ghobrial","year":"2019","unstructured":"Ghobrial C, Sobhy R, Mogahed E et al (2019) Is sofosbuvir\/ledipasvir safe for the hearts of children with hepatitis C virus? Dig Liver Dis 51(2):258\u2013262","journal-title":"Dig Liver Dis"},{"issue":"6","key":"70_CR21","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1053\/j.gastro.2015.07.051","volume":"149","author":"S Renet","year":"2015","unstructured":"Renet S, Chaumais MC, Antonini T et al (2015) Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. Gastroenterology 149(6):1378\u20131380.e1","journal-title":"Gastroenterology"},{"issue":"3","key":"70_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2174\/1574887112666170725132044","volume":"12","author":"S Rouabhia","year":"2017","unstructured":"Rouabhia S, Baghazza S, Sadouki H et al (2017) Ventricular extrasystoles after first dose of sofosbuvir in a patient treated with propranolol but not with amiodarone: a case report. Rev Recent Clin Trials 12(3):159\u2013161","journal-title":"Rev Recent Clin Trials"},{"issue":"5","key":"70_CR23","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0895-7061(98)00252-0","volume":"12","author":"M Fukuhara","year":"1999","unstructured":"Fukuhara M, Matsumura K, Ohmori S (1999 May) Effects of interferon on circadian changes in blood pressure and heart rate variability in patients with chronic hepatitis. Am J Hypertens. 12(5):519\u2013523","journal-title":"Am J Hypertens."},{"issue":"2","key":"70_CR24","first-page":"114","volume":"11","author":"J Osztovits","year":"2011","unstructured":"Osztovits J, Horvath E, Tax J (2011 Feb) Reversible autonomic dysfunction during antiviral treatment in patients with chronic hepatitis C virus infection: anti-HCV therapy and autonomic function. Hepat Mon. 11(2):114\u2013118","journal-title":"Hepat Mon."},{"issue":"Suppl 1","key":"70_CR25","doi-asserted-by":"publisher","first-page":"S163","DOI":"10.1016\/S0753-3322(05)80025-3","volume":"59","author":"B Takase","year":"2005","unstructured":"Takase B, Hamabe A, Uehata A (2005 Oct) Recombinant interferon alpha treatment decreases heart rate variability indices and impairs exercise tolerance in patients with chronic hepatitis. Biomed Pharmacother. 59(Suppl 1):S163\u2013S168","journal-title":"Biomed Pharmacother."}],"container-title":["The Egyptian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-020-00070-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43044-020-00070-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-020-00070-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:12:18Z","timestamp":1625098338000},"score":1,"resource":{"primary":{"URL":"https:\/\/tehj.springeropen.com\/articles\/10.1186\/s43044-020-00070-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["70"],"URL":"https:\/\/doi.org\/10.1186\/s43044-020-00070-4","relation":{},"ISSN":["2090-911X"],"issn-type":[{"type":"electronic","value":"2090-911X"}],"subject":[],"published":{"date-parts":[[2020,7,1]]},"assertion":[{"value":"12 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Approval of Ain Shams University ethical committee was obtained for this study in January 2019 (Committee reference number: not applicable). Written informed consents were provided by all participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}